

Daniele Pastori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/649549/publications.pdf>

Version: 2024-02-01

277
papers

7,208
citations

61857

43
h-index

85405

71
g-index

286
all docs

286
docs citations

286
times ranked

9798
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. <i>Heart Failure Reviews</i> , 2023, 28, 667-681.	1.7	14
2	Adherence to the "Atrial Fibrillation Better Care"™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes" A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 406-414.	1.8	219
3	Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 441-451.	1.1	28
4	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. <i>Europace</i> , 2022, 24, 375-383.	0.7	13
5	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Thrombosis Research</i> , 2022, 209, 69-74.	0.8	8
6	REPLY to "Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome" <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	1
7	A Meta-Analysis of Plasma Homocysteine in Buerger's Disease. <i>Thrombosis and Haemostasis</i> , 2022, , .	1.8	0
8	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry. <i>Platelets</i> , 2022, , 1-6.	1.1	0
9	Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 720.	1.4	5
10	Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 1260.	1.7	10
11	Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. <i>Nutrients</i> , 2022, 14, 1127.	1.7	22
12	Safety of the oral factor Xla inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. <i>Lancet, The</i> , 2022, 399, 1383-1390.	6.3	131
13	Aging-Related Decline of Autophagy in Patients with Atrial Fibrillation" A Post Hoc Analysis of the ATHERO-AF Study. <i>Antioxidants</i> , 2022, 11, 698.	2.2	5
14	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Journal of Autoimmunity</i> , 2022, 129, 102832.	3.0	3
15	Clinical Phenotypes of Atrial Fibrillation and Mortality Risk" A Cluster Analysis from the Nationwide Italian START Registry. <i>Journal of Personalized Medicine</i> , 2022, 12, 785.	1.1	4
16	Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department. <i>Internal and Emergency Medicine</i> , 2022, 17, 1777-1784.	1.0	7
17	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	1.0	21
18	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2021, 46, 100410.	1.1	7

#	ARTICLE	IF	CITATIONS
19	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , 2021, 322, 245-249.	0.8	1
20	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13771.	0.8	14
21	Anticoagulation in patients with advanced liver disease: an open issue. <i>Internal and Emergency Medicine</i> , 2021, 16, 61-71.	1.0	7
22	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2021, 141, 1-6.	0.7	5
23	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2021, 96, 658-665.	1.4	22
24	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021, 327, 176-182.	0.8	10
25	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605,771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f11-f19.	1.4	40
26	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , 2021, 75, e14064.	0.8	1
27	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.	1.0	9
28	Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2683-2684.	2.4	6
29	Sex-Related Differences in the Association between Metabolic Syndrome and Gallstone Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1958.	1.2	3
30	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. <i>Cancer</i> , 2021, 127, 2122-2129.	2.0	45
31	Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?. <i>Digestive and Liver Disease</i> , 2021, 53, 383-384.	0.4	7
32	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021, 85, 80-85.	1.0	21
33	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 2063-2068.	1.0	5
34	Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the C ₂ HEST Score: The West Birmingham Atrial Fibrillation Project. <i>Journal of the American Heart Association</i> , 2021, 10, e017519.	1.6	10
35	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , 2021, 26, 1425.	1.7	12
36	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , 2021, 165, 105418.	3.1	21

#	ARTICLE	IF	CITATIONS
37	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients. <i>Italian Journal of Emergency Medicine</i> , 2021, 10, .	0.0	3
38	Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead. <i>Thrombosis and Haemostasis</i> , 2021, 121, 700-702.	1.8	0
39	The Atrial Fibrillation Better Care (ABC) pathway in atrial fibrillation: a systematic review and meta-analysis of 285,000 patients. <i>Europace</i> , 2021, 23, .	0.7	4
40	Nox2 up-regulation and hypoalbuminemia in patients with type 2 diabetes mellitus. <i>Free Radical Biology and Medicine</i> , 2021, 168, 1-5.	1.3	5
41	Performance of the C2HEST score to predict sustained atrial high-rate episodes in patients implanted with cardiac implantable electronic device. <i>Europace</i> , 2021, 23, .	0.7	0
42	Acute atrial ischemia associates with early but not late new-onset atrial fibrillation in STEMI patients treated with primary PCI: relationship with in-hospital outcomes. <i>Europace</i> , 2021, 23, .	0.7	0
43	Risks of thromboembolism, mortality and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. <i>Europace</i> , 2021, 23, .	0.7	1
44	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 28-36.	1.6	25
45	Comparison of bleeding risk scores in patients with atrial fibrillation and cancer. <i>Europace</i> , 2021, 23, .	0.7	0
46	Isoprostanes in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102821.	2.5	5
47	Time to hospitalisation, CT pulmonary involvement and in-hospital death in COVID-19 patients in an Emergency Medicine Unit. <i>International Journal of Clinical Practice</i> , 2021, 75, e14426.	0.8	5
48	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2021, 12, 695961.	1.6	8
49	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7193.	1.8	26
50	Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3180.	1.0	9
51	Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study. <i>Nutrients</i> , 2021, 13, 2811.	1.7	13
52	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715878.	1.1	39
53	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8993.	1.2	10
54	Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2904-2911.	1.1	33

#	ARTICLE	IF	CITATIONS
55	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 698008.	1.6	20
56	The challenge of cardiovascular prevention in NAFLD. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 877-878.	3.7	5
57	Prevention and management of type II diabetes chronic complications: the role of polyphenols (Mini-Review). <i>Current Medicinal Chemistry</i> , 2021, 28, .	1.2	3
58	Commentary on "Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial". <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 699-701.	0.7	0
59	Acute atrial ischemia associates with early but not late new-onset atrial fibrillation in STEMI patients treated with primary PCI: relationship with in-hospital outcomes. <i>Journal of Cardiology</i> , 2021, 78, 368-374.	0.8	6
60	Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns. <i>HIV Medicine</i> , 2021, 22, 434-444.	1.0	4
61	The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors. <i>Antioxidants</i> , 2021, 10, 146.	2.2	35
62	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. <i>Cerebrovascular Diseases</i> , 2021, 50, 245-261.	0.8	32
63	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronisation devices. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
64	Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer. <i>European Heart Journal</i> , 2021, 42, .	1.0	1
65	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	0.8	35
66	Thrombosis in pre- and post-vaccination phase of COVID-19. <i>European Heart Journal Supplements</i> , 2021, 23, E184-E188.	0.0	5
67	Early vs late new-onset atrial fibrillation in STEMI patients: pathophysiological mechanisms and relationship with in-hospital outcomes. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
68	High D-dimer levels in patients with Takotsubo syndrome: 2.5 years follow-up. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
69	Effect of prophylactic and therapeutic low molecular weight heparins on mortality in 15,704 COVID-19 patients. A systematic review and a meta-analysis. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
70	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 779503.	1.1	8
71	Oxidative Stress in the Pathogenesis of Antiphospholipid Syndrome: Implications for the Atherothrombotic Process. <i>Antioxidants</i> , 2021, 10, 1790.	2.2	8
72	Prevalence of heart failure with preserved ejection fraction in antiphospholipid antibodies syndrome. The multicenter ATHERO-APS study. <i>European Heart Journal</i> , 2021, 42, .	1.0	0

#	ARTICLE	IF	CITATIONS
73	D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 102.	0.9	10
74	231 In-hospital outcomes following an acute coronary syndrome in patients with liver fibrosis: results from the real-world observational registry of acute coronary syndromes (REALE-ACS). <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
75	Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 2020, 109, 96-102.	1.5	35
76	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. <i>Internal and Emergency Medicine</i> , 2020, 15, 135-143.	1.0	21
77	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events: A Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2324-2331.e4.	2.4	136
78	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 513-520.	1.4	11
79	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. <i>Hepatology</i> , 2020, 72, 470-485.	3.6	203
80	Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094579.	0.7	8
81	Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events. <i>American Journal of Cardiology</i> , 2020, 132, 72-78.	0.7	6
82	Statins reduce major adverse limb events and mortality in patients with peripheral artery disease. <i>Atherosclerosis</i> , 2020, 315, e53.	0.4	0
83	Impaired HDL cholesterol efflux capacity in subjects with metabolically- but not genetically- driven non-alcoholic fatty liver disease (NAFLD). <i>Atherosclerosis</i> , 2020, 315, e155.	0.4	0
84	Liver fibrosis and cardiovascular events in non-alcoholic fatty liver disease. The prospective cohort plinio study. <i>Atherosclerosis</i> , 2020, 315, e48.	0.4	0
85	Lipid profile, oxidative stress and platelets activation after albumin infusion in congenital analbuminemia. <i>Atherosclerosis</i> , 2020, 315, e84.	0.4	0
86	Family History of Atrial Fibrillation and Risk of Cardiovascular Events. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008477.	2.1	3
87	Clinical and pharmacological characteristics of elderly patients admitted for bleeding: impact on in-hospital mortality. <i>Annals of Medicine</i> , 2020, 52, 413-422.	1.5	4
88	Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1291-1298.	1.6	15
89	Features of severe COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13378.	1.7	141
90	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. <i>Clinical and Translational Science</i> , 2020, 13, 1071-1076.	1.5	36

#	ARTICLE	IF	CITATIONS
91	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <i>Nutrients</i> , 2020, 12, 2762.	1.7	89
92	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Biomedicines</i> , 2020, 8, 625.	1.4	21
93	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2455-2463.	1.1	24
94	Nutrition, Thrombosis, and Cardiovascular Disease. <i>Circulation Research</i> , 2020, 126, 1415-1442.	2.0	35
95	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 866-875.	1.8	52
96	SARS-CoV-2 and myocardial injury: a role for Nox2?. <i>Internal and Emergency Medicine</i> , 2020, 15, 755-758.	1.0	18
97	Antiphospholipid antibodies in end-stage renal disease: A systematic review and meta-analysis. <i>Hemodialysis International</i> , 2020, 24, 383-396.	0.4	4
98	Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4120.	1.8	13
99	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 1732.	1.7	33
100	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , 2020, 127, 400-401.	2.0	60
101	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , 2020, 105, 562-572.	1.7	81
102	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATheroAF study. <i>International Journal of Cancer</i> , 2020, 147, 3424-3430.	2.3	8
103	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. <i>Hepatology Communications</i> , 2020, 4, 1034-1040.	2.0	22
104	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00116.	1.3	10
105	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020, 190, 588-593.	1.2	14
106	Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00123.	1.3	30
107	Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. <i>Thrombosis and Haemostasis</i> , 2020, 120, 949-956.	1.8	183
108	A novel role of MMP2 in regulating platelet NOX2 activation. <i>Free Radical Biology and Medicine</i> , 2020, 152, 355-362.	1.3	15

#	ARTICLE	IF	CITATIONS
109	PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. <i>Antioxidants</i> , 2020, 9, 296.	2.2	28
110	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 355-360.	1.0	16
111	Integrated care management of patients with atrial fibrillation—far from optimal. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 176-178.	0.3	0
112	Paroxysmal nocturnal hemoglobinuria and cardio-respiratory system: new pathophysiological evidences. , 2020, , .		0
113	The platelets behaviour in non-alcoholic fatty liver disease. A potential role for antiplatelets drugs?. <i>European Heart Journal</i> , 2020, 41, .	1.0	2
114	Clinical phenotypes of atrial fibrillation and risk of mortality: a cluster analysis. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
115	Incidence, type and prediction of death in anticoagulated patients with atrial fibrillation: a post-hoc analysis from the SPORTIF trials. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
116	The Atrial fibrillation Better Care (ABC) pathway is associated to a lower incidence of cardiac complications in patients with atrial fibrillation: a report from the ATHERO-AF study. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
117	Risk of cardiovascular events in patients with atrial fibrillation and cancer. Data from the ATHERO-AF cohort. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
118	Identifying at-risk subjects for sustained atrial high-rate episodes using the C2HEST score: the West Birmingham AF project. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
119	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. <i>European Journal of Nutrition</i> , 2019, 58, 843-851.	1.8	25
120	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2301-2308.	1.9	15
121	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. <i>Atherosclerosis</i> , 2019, 289, 195-200.	0.4	12
122	Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 786-790.	2.5	4
123	Off-label use of ceftaroline fosamil: A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 562-571.	1.1	29
124	P3472 Modifications of renal function in atrial fibrillation patients treated with different oral anticoagulants: a multicentre cohort study. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
125	Anticoagulants in Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2436.	1.2	0
126	Lysosomal Acid Lipase Activity And Hepatic Fibrosis In Non-Alcoholic Fatty Liver Disease. <i>Atherosclerosis</i> , 2019, 287, e122.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e012596.	1.6	23
128	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	0.7	20
129	Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. <i>Thrombosis Research</i> , 2019, 183, 28-32.	0.8	13
130	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	1.8	8
131	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , 2019, 124, 723-728.	0.7	11
132	Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2019, 14, 1199-1201.	1.0	1
133	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 561-576.	1.2	20
134	Statins and non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1787-1787.	1.9	3
135	Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2019, 292, 126-130.	0.8	19
136	Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 519-525.	2.5	28
137	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 17.	1.1	8
138	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. <i>Biochemical Pharmacology</i> , 2019, 163, 111-118.	2.0	16
139	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. <i>Clinical Research in Cardiology</i> , 2019, 108, 1034-1041.	1.5	15
140	P5454PCSK9 as a predictor of cardiovascular events in atrial fibrillation: role of platelet activation. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
141	Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2019, 16, 91-98.	1.5	31
142	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 508-515.	1.1	19
143	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1261-1267.	1.4	89
144	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , 2019, 132, 856-861.	0.6	67

#	ARTICLE	IF	CITATIONS
145	A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects. <i>Chest</i> , 2019, 155, 510-518.	0.4	124
146	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2019, 25, 4172-4180.	1.4	23
147	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 6, 1.	0.2	1
148	Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome. <i>Sleep Medicine</i> , 2018, 43, 66-70.	0.8	66
149	Localization of lipopolysaccharide from <i>Escherichia Coli</i> into human atherosclerotic plaque. <i>Scientific Reports</i> , 2018, 8, 3598.	1.6	88
150	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. <i>Scientific Reports</i> , 2018, 8, 3702.	1.6	59
151	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2018, 54, 34-39.	1.0	18
152	Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 2018, 107, 772-777.	1.5	28
153	Antioxidant activity from extra virgin olive oil via inhibition of hydrogen peroxide-mediated NADPH-oxidase 2 activation. <i>Nutrition</i> , 2018, 55-56, 36-40.	1.1	13
154	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. <i>International Journal of Cardiology</i> , 2018, 261, 92-98.	0.8	37
155	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 71, 706-707.	1.2	0
156	Reply. <i>Gastroenterology</i> , 2018, 154, 761-762.e1.	0.6	2
157	Dementia and Atrial Fibrillation: A Dangerous Combination for Ischemic Stroke and Mortality. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1129-1132.	1.2	13
158	Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants. <i>American Heart Journal</i> , 2018, 198, 166-168.	1.2	5
159	Severity of OSAS, CPAP and cardiovascular events: A follow-up study. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12908.	1.7	31
160	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 255, 69-73.	0.8	21
161	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 537-541.	1.6	7
162	Response to Duret et al.. <i>American Journal of Gastroenterology</i> , 2018, 113, 775-776.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. <i>Atherosclerosis</i> , 2018, 274, 29-34.	0.4	13
164	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , 2018, 132, 149-159.	3.1	9
165	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , 2018, 50, 288-302.	1.5	10
166	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	1.0	29
167	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 200, 32-36.	1.2	13
168	Progressive reduction of blood lysosomal acid lipase activity according to stage of adult chronic liver disease and altered enzymatic cellular distribution in cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 37.	0.4	0
169	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>Data in Brief</i> , 2018, 17, 830-836.	0.5	5
170	Ageing and Adherence to the Mediterranean Diet: Relationship with Cardiometabolic Disorders and Polypharmacy. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 73-81.	1.5	13
171	P1882 Relationship between inflammation and atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
172	Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. <i>Journal of the American Heart Association</i> , 2018, 7, e009509.	1.6	9
173	Assessment of blood hydrogen peroxide break-down activity (HBA) in healthy subjects and in patients with atrial fibrillation: relation to cardiovascular events. <i>Atherosclerosis</i> , 2018, 275, e252-e253.	0.4	1
174	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2018, 7, 378.	1.0	36
175	Enhanced urinary excretion of thromboxane B2 in non-alcoholic fatty liver disease. Implication for antiplatelet treatment. <i>Atherosclerosis</i> , 2018, 275, e65-e66.	0.4	2
176	Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1847-1849.	1.8	1
177	Mechanisms of digoxin-related platelet activation in atrial fibrillation patients: In vivo and in vitro study. <i>Atherosclerosis</i> , 2018, 275, e95-e96.	0.4	0
178	Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481879356.	1.4	29
179	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>International Journal of Cardiology</i> , 2018, 264, 58-63.	0.8	69
180	Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus. <i>Diabetic Medicine</i> , 2018, 35, 1134-1135.	1.2	1

#	ARTICLE	IF	CITATIONS
181	Increased gut permeability is associated with oxidative stress in patients with NAFLD. <i>Journal of Hepatology</i> , 2018, 68, S821-S822.	1.8	0
182	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). <i>Annals of Medicine</i> , 2018, 50, 511-518.	1.5	12
183	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1286-1292.	0.7	4
184	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. <i>International Journal of Molecular Sciences</i> , 2018, 19, 603.	1.8	7
185	Oxidative stress and cardiovascular disease: new insights. <i>Kardiologia Polska</i> , 2018, 76, 713-722.	0.3	150
186	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 88-95.	1.1	74
187	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017, 231, 143-149.	0.8	22
188	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renal disease progression by aspirin in diabetic patients (LEDA) trial. Rationale and study design. <i>American Heart Journal</i> , 2017, 189, 120-127.	1.2	10
189	Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2017, 153, 480-487.e1.	0.6	301
190	Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 890-895.	1.1	26
191	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. <i>Scientific Reports</i> , 2017, 7, 3797.	1.6	8
192	Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	105
193	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017, 262, 179-184.	0.4	19
194	ADHERENCE TO MEDITERRANEAN DIET AND NON ALCOHOLIC FATTY LIVER DISEASE: IMPACT ON METABOLIC PROFILE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1868.	1.2	0
195	Visceral fat evaluated by ultrasound is associated with insulin resistance and liver damage in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, e32.	1.1	1
196	Reply to: "Monitoring antivitamin K anticoagulants in antiphospholipid syndrome: A challenge in quality". <i>Atherosclerosis</i> , 2017, 256, 148-149.	0.4	0
197	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. <i>American Journal of Gastroenterology</i> , 2017, 112, 1832-1839.	0.2	109
198	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 1083-1124.	2.5	92

#	ARTICLE	IF	CITATIONS
199	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. <i>Internal and Emergency Medicine</i> , 2017, 12, 1159-1165.	1.0	16
200	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1455-1462.	1.2	57
201	Direct oral anticoagulant reversal: how, when and issues faced. <i>Expert Review of Hematology</i> , 2017, 10, 1005-1022.	1.0	4
202	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. <i>Scientific Reports</i> , 2017, 7, 15756.	1.6	45
203	Under-prescription of statins in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 161-167.	1.1	45
204	Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1558-1570.	1.8	56
205	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 856-863.	1.8	30
206	Short-term modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F ₂ in HIV-1 patients on abacavir-based therapies. <i>HIV Medicine</i> , 2016, 17, 774-777.	1.0	0
207	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	143
208	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , 2016, 113, 484-489.	3.1	22
209	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2016, 223, 619-624.	0.8	11
210	Pentraxin 3 "A Link Between Obesity, Inflammation and Vascular Disease?". <i>Circulation Journal</i> , 2016, 80, 327-328.	0.7	5
211	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 751-755.	2.5	15
212	Spleen Dimensions Evaluated by Ultrasound are Inversely Associated with Lysosomal Acid Lipase Activity in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Hepatology</i> , 2016, 64, S489.	1.8	0
213	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2016, 36, 74-80.	1.0	15
214	Age-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	51
215	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 107-114.	1.7	45
216	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists. <i>Medicine (United States)</i> , 2016, 95, e2895.	0.4	50

#	ARTICLE	IF	CITATIONS
217	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , 2016, 8, 275-283.	0.6	36
218	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , 2016, 11, 199-204.	1.0	41
219	Reply to: "Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke". <i>International Journal of Cardiology</i> , 2016, 202, 934-935.	0.8	0
220	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , 2016, 244, 48-50.	0.4	14
221	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. <i>Oncotarget</i> , 2016, 7, 39143-39147.	0.8	18
222	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 617-624.	1.8	50
223	Does Lysosomal Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28014-28021.	1.8	18
224	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. <i>World Journal of Hepatology</i> , 2015, 7, 1325.	0.8	152
225	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. <i>Chest</i> , 2015, 147, 1644-1650.	0.4	59
226	HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. <i>Journal of Infection</i> , 2015, 70, 651-658.	1.7	17
227	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , 2015, 5, e008026-e008026.	0.8	21
228	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015, 116, 647-651.	0.7	110
229	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , 2015, 17, 1223-1228.	0.7	13
230	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 490-497.e1.	1.2	26
231	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , 2015, 70, 961-966.	2.7	38
232	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2015, 47, 4-11.	0.4	121
233	P1049 : Lysosomal Acid Lipase activity in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 62, S742.	1.8	1
234	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , 2015, 26, e31-e33.	1.0	2

#	ARTICLE	IF	CITATIONS
235	Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects. <i>Nutrition and Diabetes</i> , 2015, 5, e172-e172.	1.5	74
236	Response to Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality. <i>International Journal of Cardiology</i> , 2015, 189, 247-248.	0.8	0
237	Relation of Nonalcoholic Fatty Liver Disease and Framingham Risk Score to Flow-Mediated Dilatation in Patients With Cardiometabolic Risk Factors. <i>American Journal of Cardiology</i> , 2015, 115, 1402-1406.	0.7	24
238	Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 682-687.	2.5	49
239	Nox-2 up-regulation and platelet activation: Novel insights. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 50-55.	1.0	32
240	Obstructive Sleep Apnea and the Metabolic Syndrome. , 2015, , 177-184.		0
241	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e113.	1.3	25
242	Reply to "The relation between flow mediated dilation and atrial fibrillation" by S. Balta. <i>International Journal of Cardiology</i> , 2015, 201, 225-226.	0.8	0
243	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. <i>EBioMedicine</i> , 2015, 2, 750-754.	2.7	51
244	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 201, 513-516.	0.8	57
245	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , 2015, 34, 899-903.	2.3	25
246	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 180, 1-5.	0.8	33
247	Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2015, 179, 139-143.	0.8	24
248	Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.. <i>Current Pharmaceutical Design</i> , 2015, 21, 5945-5950.	0.9	5
249	Modern approach to the clinical management of non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 8341.	1.4	61
250	Total Adiponectin Is Inversely Associated with Platelet Activation and CHA ₂ DS ₂ -VASc Score in Anticoagulated Patients with Atrial Fibrillation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	1.4	19
251	P848 SERUM CYTOKERATIN-18 IS ASSOCIATED WITH OXIDATIVE STRESS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S354.	1.8	0
252	P825 NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH REDUCED SERUM CHOLESTEROL-ADJUSTED VITAMIN E LEVELS. <i>Journal of Hepatology</i> , 2014, 60, S346.	1.8	0

#	ARTICLE	IF	CITATIONS
253	Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?. Internal and Emergency Medicine, 2014, 9, 123-131.	1.0	41
254	Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. Europace, 2014, 16, 1107-1116.	0.7	47
255	Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia. Journal of the American College of Cardiology, 2014, 64, 1917-1925.	1.2	134
256	Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. Atherosclerosis, 2014, 235, 649-658.	0.4	62
257	Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends in Cardiovascular Medicine, 2014, 24, 142-148.	2.3	34
258	Is NOX2 Upregulation Implicated in Myocardial Injury in Patients with Pneumonia?. Antioxidants and Redox Signaling, 2014, 20, 2949-2954.	2.5	25
259	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. European Journal of Internal Medicine, 2014, 25, 566-570.	1.0	23
260	P812 NOX2-GENERATED OXIDATIVE STRESS IS INCREASED IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE INDEPENDENTLY FROM METABOLIC SYNDROME. Journal of Hepatology, 2014, 60, S341.	1.8	0
261	NOX2-generated oxidative stress is increased in patients with non-alcoholic fatty liver disease independently from metabolic syndrome. Digestive and Liver Disease, 2014, 46, e27.	0.4	0
262	Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1112.	0.5	24
263	Abstract 16732: Urinary 11-Dehydro-Thromboxane B2 is Associated With Vascular and Non-Vascular Events in Atrial Fibrillation Patients. Circulation, 2014, 130, .	1.6	0
264	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. International Journal of Cardiology, 2013, 168, 3241-3247.	0.8	12
265	Vitamin e serum level, a new tool to stratify bleeding risk in patients receiving oral anticoagulant therapy. European Heart Journal, 2013, 34, P534-P534.	1.0	0
266	Vitamin e serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. European Heart Journal, 2013, 34, P5606-P5606.	1.0	0
267	Vitamin E Serum Levels and Bleeding Risk in Patients Receiving Oral Anticoagulant Therapy: a Retrospective Cohort Study. Journal of the American Heart Association, 2013, 2, e000364.	1.6	36
268	Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. Heart, 2012, 98, 1063-1066.	1.2	32
269	Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2. Circulation, 2012, 126, 92-103.	1.6	148
270	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study. American Journal of Hematology, 2012, 87, 384-387.	2.0	25

#	ARTICLE	IF	CITATIONS
271	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. <i>BMC Infectious Diseases</i> , 2011, 11, 341.	1.3	7
272	Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. <i>AIDS Research and Therapy</i> , 2011, 8, 9.	0.7	3
273	Anoxia-Reoxygenation Enhances Platelet Thromboxane A ₂ Production via Reactive Oxygen Species-Generated NOX2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1766-1771.	1.1	35
274	Immunomodulatory Effects of Intravenous Immunoglobulins (IVIGs) in HIV-1 Disease: A Systematic Review. <i>International Reviews of Immunology</i> , 2011, 30, 44-66.	1.5	7
275	Undifferentiated Connective Tissue Disease - An Unsolved Problem: Revision of Literature and Case Studies. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 271-278.	1.0	11
276	Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals. <i>Aids</i> , 2009, 23, 2233-2234.	1.0	3
277	Optical coherence tomography-derived lipid core burden index and clinical outcomes: results from the CLIMA registry. <i>European Heart Journal Cardiovascular Imaging</i> , 0, , .	0.5	7